SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that it will present the first preclinical data on ATG-207 (αCD3-TGF-β bifunctional fusion protein) in a poster presentation at the 2026 European Congress of Rheumatology (EULAR 2026), taking place from June 3 to 6 at Excel London in the United Kingdom. ATG-207 represents Antengene’s first disclosed program from its T cell-mediated autoimmune disease research efforts.

T cell-mediated autoimmune diseases are characterized by sustained activation of pathogenic effector T cells and insufficient or unstable regulatory T cell function, resulting in an inability to establish durable immune tolerance. These diseases remain an area of significant unmet medical need, as existing anti-inflammatory therapies may not sufficiently eliminate persistent pathogenic effector T cells or restore long-term immune balance. ATG-207 is designed to address these challenges through a differentiated dual mechanism that integrates CD3-mediated T cell modulation with localized, TGFβRIII-biased TGF-β activity, with the goal of selectively suppressing pathogenic T cells while promoting regulatory T cell induction and immune tolerance.

The abstract selected for poster presentation at EULAR 2026 describes preclinical studies evaluating ATG-207’s receptor binding, T cell receptor modulation, regulatory T cell induction, cytokine release profile and in vivo activity in models of T cell-mediated autoimmune disease. In these studies, ATG-207 showed preferential binding to TGFβRIII, downregulated surface T cell receptor expression, induced regulatory T cells in vitro and demonstrated therapeutic efficacy through a mouse surrogate molecule in an experimental autoimmune encephalomyelitis model. Compared with an unbiased αCD3-TGF-β fusion protein control, ATG-207 or its mouse surrogate induced substantially lower levels of proinflammatory cytokine release in human whole blood assays and in mice.

Details of the Poster
Title: A masked and TGFβRIII-biased αCD3-TGF-β fusion protein promotes regulatory T cell induction and immune tolerance
Poster Number: POS-1110
Track: Basic and Translational
Topic: Across diseases
Sub-Topic: Adult Rheumatology
Session: Poster View VIII
Room: Poster View
Date: June 6, 2026
Time: 10:15 British Summer Time / 17:15 Beijing Time

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using Antengene’s proprietary AnTenGager^® platform.

AnTenGager^®, is Antengene’s proprietary TCE 2.0 platform, featuring “2+1” bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO^® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: donald.lung@antengene.com 

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com

SINGAPORE, June 3, 2026 /PRNewswire/ — Ahead of the upcoming school holidays, Agoda data shows Indonesian travelers planning a wide mix of domestic and international trips, from island escapes to city breaks and nature retreats. Accommodation searches for destinations such as Batam and Phu Quoc rose by more than 200% compared to the same period last year.

School holidays remain one of the key travel periods for Indonesian families, and this year travelers are combining meaningful journeys with leisure experiences.

International destinations are seeing a rise in interest

Beach and island escapes continue to see strong interest, with destinations such as Phu Quoc Island in Vietnam recording a 224% increase, reflecting rising interest in accessible, visa-friendly getaways. Phu Quoc Island is gaining popularity for its white-sand beaches, the world’s longest sea-crossing cable car, and expansive entertainment hubs like VinWonders and Vinpearl Safari. 

Chinese cities Hangzhou and Guangzhou also saw increased interest, with searches up 122% and 80% respectively. Families are exploring the cities for shopping, food, theme parks, and urban attractions, while destinations such as Jeju in South Korea also recorded a 69% increase in searches for family holidays.

Domestic destinations gain traction among family travelers

Beach and island destinations also see strong growth domestically, with Batam Island recording a 236% increase in accommodation searches, making it one of the most popular destinations for the holiday period among families. With pristine beaches, vibrant culinary scene, and proximity to Singapore, Batam continues to appeal to Indonesian travelers as a convenient short-haul getaway for families.

Domestic cities such as Makassar and Cirebon are also seeing growing interest, up 62% and 53% respectively, supported by their culinary and cultural appeal. Nature destinations, particularly around Lake Toba such as Samosir (36%) and Parapat (47%), along with Bukittinggi (39%), continue to attract travelers seeking scenic landscapes and cooler climates during the school holiday period.

Gede Gunawan, Senior Country Director, Indonesia at Agoda says, “With the school holiday just around the corner, these trending destinations indicate an exciting travel season ahead, promising new experiences for Indonesian travelers both domestically and internationally. The growth in accommodation searches highlights the diverse travel aspirations of Indonesians. Agoda is committed to making these journeys easier and more memorable, with a wide range of options tailored to every traveler’s needs.”

With over 6 million holiday properties, more than 130,000 flight routes, and over 300,000 activities, Agoda enables travelers to plan and combine every part of the journey in one place. Running from 7 May to 21 May, Agoda’s 21st Birthday Sale will offer up to 60% off on hotel bookings, with a special flash sale of up to 70% on 19 May and exclusive deals on flights and activities. Discover more on Agoda’s mobile app or at Agoda.com.

TAIPEI, June 3, 2026 /PRNewswire/ — ASRock Rack Inc., a leading innovative server company, today announced its latest portfolio of AI-native infrastructure designed for the era of agentic AI. Showcasing at COMPUTEX 2026 (Booth No.: R0514), ASRock Rack is introducing the new 2UXGM-VERA2 system powered by NVIDIA Vera CPU. The company is also presenting its next-generation AI platform portfolio for AI factories, inference cloud deployments, and edge AI applications, delivering a unified vision for the next wave of AI computing at every scale.

Accelerating the Era of Agentic AI

The AI industry is undergoing a fundamental transformation as scaling laws move beyond model size into the era of agentic AI. This shift from “human talking to AI” to “AI talking to AI” has placed CPU execution on the critical path. To enable this next wave, ASRock Rack is introducing the 2UXGM-VERA2, powered by NVIDIA Vera CPU, a processor purpose-built for the age of AI. Combining custom-designed NVIDIA Olympus cores with high-bandwidth LPDDR5X memory and NVIDIA Scalable Coherency Fabric, Vera delivers a unified compute architecture that completes complex agentic and reinforcement learning workloads 50% faster than traditional CPU infrastructure.

“The AI industry is entering a new frontier where systems move beyond generating responses to executing autonomous actions,” said Weishi Sa, President of ASRock Rack. “NVIDIA Vera is the CPU for the age of AI, providing the high-speed execution layer that turns model reasoning into autonomous action at the speed of the AI factory. To power this next frontier, ASRock Rack is planning a comprehensive new lineup of AI servers powered by NVIDIA Vera, ranging from standalone CPU servers to scale-up AI servers incorporating NVIDIA HGX Vera Rubin NVL8 for every type of AI factory and data center deployment.”

Driving the AI Computing Wave at Every Scale

At COMPUTEX 2026, ASRock Rack is showcasing AI server platforms integrated with advanced liquid-cooling solutions from ecosystem partners. The company’s exhibit highlights the NVIDIA Vera Rubin NVL72, cooled with a double-rack-width liquid-to-air coolant distribution unit (CDU) for next-generation AI factory environments. Also on display are liquid-cooled systems incorporating NVIDIA HGX Rubin NVL8, including the fully liquid-cooled 2U16X-GNR2/DLC and the 5U16X-GNR2/DLC, which combines liquid cooling for CPU and GPU with sufficient airflow for flexible integration of other key peripherals. The company is also demonstrating rack-scale liquid-cooling solutions with in-row CDU for high-density AI deployments.

In addition to its rack-scale solutions, ASRock Rack will demonstrate a diverse lineup of MGX-based servers for enterprise and edge environments. This includes the 6UXGM-GNR2/DLC, supporting up to eight liquid-cooled NVIDIA RTX PRO 6000 Blackwell Server Edition GPUs to accelerate enterprise AI and visual computing. Also featured is the 4UXGM-GNR2 CX8, a NVIDIA RTX PRO Server optimized for inference cloud environments. Bridging to the industrial edge, the 2UXGI-Thor, built on NVIDIA IGX Thor platform, showcases capabilities for Physical AI, enabling real-time sensor processing and functional safety for next-generation autonomous robotics and medical applications.

Visit ASRock Rack at COMPUTEX 2026

Visitors to COMPUTEX 2026 are invited to explore ASRock Rack’s latest AI platforms from edge to cloud and experience live agentic AI demonstrations at Taipei Nangang Exhibition Center, Hall 2, Booth No. R0514.

For more information, please visit https://www.asrockrack.com.

About ASRock Rack Inc.

ASRock Rack Inc., established in 2013, specialized in the field of cloud computing server hardware. While inheriting ASRock’s design concepts, “Creativity, Consideration, Cost-effectiveness,” the company is dedicated to bring the server industry out-of-the-box thinking with the passion to innovate. Leveraged by ASRock’s growing momentum and distribution channels, this young and vibrant company targets booming market of cloud computing, and commits to serving the market with user-friendly and eco-friendly do-it-yourself server hardware, featuring flexible and reliable products.

Social Media
Website: www.asrockrack.com
LinkedIn: www.linkedin.com/company/3568757
Twitter: www.twitter.com/asrockrack 

BEIJING, June 3, 2026 /PRNewswire/ — Cheung Kong Graduate School of Business (CKGSB) today announced the opening of its first permanent campus in Beijing, marking a major milestone in the school’s 23-year journey of developing leaders capable of shaping the future in an increasingly complex and uncertain world.  

Located in the heart of Beijing’s Ciqikou, or “China’s Gateway,” the new campus sits at a rare geographical and symbolic intersection in Beijing. On one side stand the Forbidden City and the Temple of Heaven, symbols of China’s rich history and civilization. On the other rises Beijing’s CBD, reflecting the country’s dynamism and innovation. Positioned between these two worlds, the campus embodies CKGSB’s role as a bridge between China’s past and future, and between China and the world. 

Founded in 2002, right after China entered the WTO, CKGSB has spent more than two decades advancing business education and management research, while helping leaders understand China’s evolving role in the global economy. The new campus strengthens the school’s ability to connect research with practice, deepen engagement with China’s business ecosystem, and contribute to global dialogue from the nation’s capital.

The 30,000-square-meter campus features a façade inspired by a vessel setting sail, reflecting CKGSB’s commitment to helping leaders navigate uncertainty and discover new opportunities. At its center is a 17-meter high atrium inspired by the ancient Greek Agora—a dynamic learning hub where faculty, students, alumni, entrepreneurs, policymakers, and scholars come together to exchange ideas and translate insight into action.

As China’s first privately-funded, research-driven business school, CKGSB focuses on developing decision makers with a global vision, social responsibility, and an innovative mindset. 95% of CKGSB’s 25,000 alumni are comprised of business leaders who collectively run one fifth of China’s most valuable brands. The new campus reflects the collective support of this community, whose contributions helped turn a long-held vision into reality.

Today, CKGSB also welcomed 275 new Executive MBA students of its Spring 2026 cohort to the new campus. 75% of these EMBA students are either chairmen or CEOs, more than half of whom run high-tech enterprises or hidden champions in China. Among them, two lead unicorn companies. 

In the coming months, the school will host lectures and conferences at the new Beijing campus exploring AI and innovation, leadership, China’s economic outlook, and the future of global business.

APIA, Samoa, June 3, 2026 /PRNewswire/ — HTX, a leading global cryptocurrency exchange, officially launched its U.S. Stock Futures TradFi Trading Contest on June 1, 2026. From now until June 11 at 12:00 (UTC), both new and existing users can trade designated pairs to compete for a share of a generous 50,000 USDT prize pool.

Breaking Down Traditional Finance Barriers: Seamless 24/7 Trading of U.S. Stock Assets

As traditional finance and the crypto market continue to converge, crypto users are showing growing demand for cross-market and diversified asset allocation.  To help global users participate in traditional financial markets with lower barriers and higher efficiency, HTX has innovatively launched the U.S. Stock Futures TradFi Trading Contest, enabling users to seize investment opportunities in global core assets within a crypto trading framework.

According to the official announcement, this event covers the world’s most highly watched traditional commodities and tech giants. On the HTX platform, users can directly use USDT to trade USDT-M Perpetual Futures for highly sought-after premium U.S. stocks and TradFi assets, including USOIL, SPX500, XAU, NVDA, TSLAX, MSTRX, GOOGL, XAG, and INTCX.

By removing the trading-time and geographical restrictions of traditional stock markets, HTX delivers a true 24/7 U.S. stock-trading experience. Users can flexibly adjust their positions according to market shifts, allowing them to capture timely trading opportunities amid global macroeconomic events, industry trends, and asset price fluctuations, ultimately achieving more efficient asset allocation and risk management.

50,000 USDT Prize Pool to Incentivize Both New and Existing Users

This trading contest features a total prize pool of 50,000 USDT, rewarding both new and existing users for their participation.

During the event, users who complete futures trades on designated pairs and reach a cumulative trading volume of 10,000 USDT will be eligible to compete for rankings and share a 47,000 USDT prize pool. Notably, the top three users by trading volume will walk away with fixed rewards of 10,000 USDT, 8,000 USDT, and 5,000 USDT, respectively.

To encourage more users to experience the unique appeal of U.S. stock futures, HTX has rolled out a dedicated 3,000 USDT prize pool for newcomers. During the event, new users who complete futures trades on designated pairs with a cumulative trading volume of 500 USDT, while maintaining a position of ≥100 USDT for at least 2 days, will have the chance to receive a 3 USDT reward. Rewards will be distributed based on the trading-volume rankings of eligible users on a first-come, first-served basis, while supplies last.

Event Details: https://www.htx.com.ph/microapps/en-us/contract-transaction/web/competitionDetail?activityId=177993903503225&bizLine=1

HTX Leads a New Trend in Crypto Trading with a User-First Approach

In recent years, as the crypto market’s user base has matured, demand for cross-asset and cross-market trading instruments has surged.  HTX continuously expands its product boundaries. While consistently optimizing trading services for mainstream crypto assets, HTX actively explores pathways for integrating traditional financial assets into the crypto trading ecosystem, providing users with a more diversified selection of investment vehicles.

The launch of the U.S. Stock Futures TradFi Trading Contest not only opens a new channel for users to participate in global core asset markets, but also further enriches HTX’s trading product lineup. Moving forward, HTX will continue to optimize the product experience centered around user needs, expand high-quality asset categories, and build a secure, transparent, and highly efficient comprehensive digital asset trading platform for global traders.

About HTX

Founded in 2013, HTX has evolved from a virtual asset exchange into a comprehensive ecosystem of blockchain businesses that span digital asset trading, financial derivatives, research, investments, incubation, and other businesses.

As a world-leading gateway to Web3, HTX harbors global capabilities that enable it to provide users with safe and reliable services. Adhering to the growth strategy of “Global Expansion, Thriving Ecosystem, Wealth Effect, Security & Compliance,” HTX is dedicated to providing quality services and values to virtual asset enthusiasts worldwide.

To learn more about HTX, please visit https://www.htx.com/ or HTX Square, and follow HTX on X, Telegram, and Discord.

SINGAPORE, June 3, 2026 /PRNewswire/ — HIMSS, a mission-driven independent society, global thought leader and advisor, will co-host the 2026 HIMSS APAC Health Conference & Exhibition 23–25 August 2026 in Singapore in strategic partnership with SingHealth, Singapore’s largest public group of healthcare institutions.

HIMSS26 APAC will convene senior health system leaders, government ministers, clinicians and technology innovators from across Asia-Pacific and beyond to address the defining challenge of the time: translating AI ambition into scalable, evidence-based impact.

Under the theme “Trust, Intelligence and Agility: Re-engineering APAC Health Systems in the AI Era,” the three-day program will combine an exclusive pre-conference CXO AI Summit, two days of main conference plenary and parallel tracks, an exhibition, curated hospital visits and executive networking to create an unparalleled environment for peer exchange, strategic insight and high-value connections.

“Health systems across Asia-Pacific have focused ambition and investment in the deployment of AI tools and capabilities. The global challenge is translating momentum into scalable, system-wide impact,” said Hal Wolf, HIMSS President and CEO. “HIMSS26 APAC will bring together leaders, frameworks and real-world evidence to guide health systems through measurable transformation. We are proud to develop this program in close partnership with our APAC Steering committee, comprised of senior healthcare executives and digital health leaders from APAC markets, to deliver the best insights at the conference.”

A Strategic Partnership with SingHealth

HIMSS26 APAC is co-hosted with SingHealth, Singapore’s largest public healthcare cluster. The partnership reflects Singapore’s position as the APAC hub for digital health innovation. Additionally, this partnership connects HIMSS26 APAC delegates directly to the team leading Singapore’s national health data strategy, AI governance frameworks and digital maturity programs.

Benedict Tan, Group Chief Digital Strategy Officer and Chief Data Officer at SingHealth and Board Member of HIMSS, will deliver keynotes at both the CXO AI Summit and the main conference opening ceremony. This reflects SingHealth’s commitment to inspire other healthcare systems to use AI with trust, transparency and measurable impact.

Three Days of High-Stakes Dialogue

The programme is built around the questions that matter most to health system leaders right now: Is AI ROI the wrong metric? What does a smart hospital look like in the age of AI? And what separates the systems that are scaling innovation from those still experimenting?

The conference opens on 23 August with an invitation-only CXO AI Summit, an executive forum challenging the conventional wisdom on AI return on investment, governance and the foundations of enterprise-scale adoption. The Summit will be anchored by keynotes from Hal Wolf and Benedict Tan, with panel discussions moderated by Dr Anne Snowdon, Chief Scientific Officer of HIMSS, and Tom Leary, HIMSS Senior Vice President and Head of Government Relations. International speakers from health systems from across the Asia-Pacific region will be announced soon.

The main conference on 24–25 August opens with a showcase of excellence in digital maturity before moving into two days of plenary keynotes, executive addresses, government perspectives from across APAC and deep-dive parallel tracks spanning AI digital foundation, clinical AI, operational AI and smart hospitals and intelligent health systems. Senior perspectives from health ministries and leading digital health organisations across South Korea, Australia, Singapore and the broader Asia-Pacific region will be featured throughout.

The programme closes with a cross-industry panel asking what healthcare can learn from other sectors already reshaped by AI, bringing together voices from health technology, clinical leadership and beyond.

Members of the press, potential media partners and podcasters interested in participating in HIMSS26 APAC are invited to email the HIMSS Communications team at press@himss.org for more information.

About HIMSS

HIMSS (the Healthcare Information and Management Systems Society) is a mission-driven independent society, a global thought leader, and an advisor dedicated to creating an informed and empowered community of providers, innovators, and individuals. HIMSS stands apart by bridging strategic and visionary ideas with practical execution, empowering health systems and governments globally to achieve measurable impact for the future of health and care.

About SingHealth

SingHealth is Singapore’s largest group of healthcare institutions, comprising an integrated network of hospitals, specialty centres, and polyclinics committed to providing quality, accessible healthcare. As a regional leader in integrated digital health, SingHealth serves as both co-host and a real-world model of how policy, infrastructure, and innovation align to support system-wide transformation.